Sfoglia per Autore
Alemtuzumab for the treatment of Sézary sindrome: clinical and immunological findings in 10 patients.
2006-01-01 Bernengo MG; Quaglino P; Comessatti A; Ortoncelli M; Novelli M; Fierro MT.
Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients.
2007-01-01 QUAGLINO P; OSELLA-ABATE S; CAPPELLO N; ORTONCELLI M; NARDO T; FIERRO MT; CAVALLO F; SAVOIA P; BERNENGO M
Low-dose intermittent Alemtuzumab in Sézary Syndrome: clinical activity, toxicity profile and immunological findings in 17 patients.
2008-01-01 Bernengo MG; Quaglino P; Comessatti A; Ortoncelli M; Novelli M; Lisa F; Fierro MT
Adult-onset cutaneous mastocytosis in monozygotic twins.
2011-01-01 Quaglino P; Mola F; Peroni A; Ortoncelli M; Di Bello C; Savoia P; Bernengo MG
Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient
2020-01-01 Quaglino P.; Fava P.; Cariti C.; Ortoncelli M.; Aimetti M.; Milan A.; Dapavo P.; Tonella L.; Ribero S.; Fierro M.T.
Toxic epidermal necrolysis and role of immune dysregulation in a patient affected by coronavirus disease
2021-01-01 Parietti, Michele; Siliquini, Niccolò; Ortoncelli, Michela; Dapavo, Paolo; Stella, Maurizio; Verrua, Roberta; Ribero, Simone; Quaglino, Pietro
Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real-life study
2021-01-01 Mastorino L.; Viola R.; Panzone M.; Avallone G.; Gallo G.; Ortoncelli M.; Cavaliere G.; Quaglino P.; Ribero S.
Dupilumab-induced Urticaria
2021-01-01 Mastorino L.; Ortoncelli M.; Virginia B.; Rolla G.; Avallone G.; Cavaliere G.; Riccardo V.; Quaglino P.; Ribero S.
Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study
2021-01-01 Dapavo P.; Siliquini N.; Mastorino L.; Avallone G.; Merli M.; Agostini A.; Cariti C.; Viola R.; Stroppiana E.; Verrone A.; Ortoncelli M.; Quaglino P.; Ribero S.
Are serious ophthalmic adverse events on dupilumab treatment for atopic dermatitis dose related?
2021-01-01 Mastorino L.; Ortoncelli M.; Avallone G.; Quaglino P.; Ribero S.
Atopic dermatitis, dupilumab and cancers: a case series
2021-01-01 Siliquini N.; Giura M.T.; Viola R.; Ribero S.; Panzone M.; Dapavo P.; Fierro M.T.; Ortoncelli M.; Quaglino P.
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study
2021-01-01 Patruno C.; Napolitano M.; Argenziano G.; Peris K.; Ortoncelli M.; Girolomoni G.; Offidani A.; Ferrucci S.M.; Amoruso G.F.; Rossi M.; Stingeni L.; Malara G.; Grieco T.; Foti C.; Gattoni M.; Loi C.; Iannone M.; Talamonti M.; Stinco G.; Rongioletti F.; Pigatto P.D.; Cristaudo A.; Nettis E.; Corazza M.; Guarneri F.; Amerio P.; Esposito M.; Belloni Fortina A.; Potenza C.; Fabbrocini G.; Angileri L.; Bianchelli T.; Borghi A.; Buligan C.; Calabrese G.; Calzavara Pinton P.; Caroppo F.; Chello C.; Dal Bello G.; Damiani G.; Fargnoli M.C.; Ferrillo M.; Galluzzo M.; Gori N.; Gualdi G.; Hansel K.; Macchia L.; Mariano M.; Nistico S.P.; Pertusi G.; Piras V.; Provenzano E.; Ravaioli G.M.; Ribero S.; Romanelli M.; Romita P.; Tolino E.; Trifiro C.
Dupilumab in HIV-positive patients with atopic dermatitis: A long-term follow-up patient and a literature review
2021-01-01 Avallone G.; Trunfio M.; Giura M.T.; Siliquini N.; Viola R.; Orofino G.; Mastorino L.; Ortoncelli M.; Quaglino P.; Ribero S.
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study
2021-01-01 Patruno C.; Fabbrocini G.; Longo G.; Argenziano G.; Ferrucci S.M.; Stingeni L.; Peris K.; Ortoncelli M.; Offidani A.; Amoruso G.F.; Talamonti M.; Girolomoni G.; Grieco T.; Iannone M.; Nettis E.; Foti C.; Rongioletti F.; Corazza M.; Veneri M.D.; Napolitano M.; Angileri L.; Bianchelli T.; Borghi A.; Calabrese G.; Chello C.; Dal Bello G.; Dastoli S.; Ferrillo M.; Galluzzo M.; Gori N.; Hansel K.; Macchia L.; Piras V.; Provenzano E.; Ribero S.; Romanelli M.; Romita P.
Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real-life experience in a tertiary referral centre
2021-01-01 Gallo G.; Rostagno E.; Siliquini N.; Stroppiana E.; Verrone A.; Ortoncelli M.; Quaglino P.; Dapavo P.; Ribero S.
Head and neck severity index is associated to a significant worsening of quality of life in atopic dermatitis patients
2021-01-01 Ribero S.; Puglisi B.; Giura M.T.; Viola R.; Siliquini N.; Quaglino P.; Ortoncelli M.
Effectiveness and Safety of Dupilumab for the Treatment of Atopic Dermatitis in Adult Cohort: a Real-Life Italian Tertiary Centre Experience.
2022-01-01 Ribero S, Giura MT, Viola R, Ramondetta A, Siliquini N, Cardone P, Tonella L, Quaglino P, Dapavo P, Panzone M, Ortoncelli M, Fierro MT.
Lichen ruber planus arising during dupilumab treatment for atopic dermatitis
2022-01-01 Mastorino, Luca; Ortoncelli, Michela; Giura, Maria T; Avallone, Gianluca; Viola, Riccardo; Quaglino, Pietro; Ribero, Simone
Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents
2022-01-01 Roccuzzo, Gabriele; Mastorino, Luca; Susca, Sara; Cariti, Caterina; Passerini, Stefania G; Sciamarrelli, Nadia; Borriello, Silvia; Macagno, Nicole; Sliquini, Niccolò; Avallone, Gianluca; Verrone, Anna; Stroppiana, Elena; Quaglino, Pietro; Ortoncelli, Michela; Dapavo, Paolo; Ribero, Simone
Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
2022-01-01 Mastorino L.; Siliquini N.; Avallone G.; Ortoncelli M.; Quaglino P.; Dapavo P.; Ribero S.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Alemtuzumab for the treatment of Sézary sindrome: clinical and immunological findings in 10 patients. | 2006 | Bernengo MG; Quaglino P; Comessatti A; Ortoncelli M; Novelli M; Fierro MT. | |
| Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients. | 2007 | QUAGLINO P; OSELLA-ABATE S; CAPPELLO N; ORTONCELLI M; NARDO T; FIERRO MT; CAVALLO F; SAVOIA P; BERNENGO M | |
| Low-dose intermittent Alemtuzumab in Sézary Syndrome: clinical activity, toxicity profile and immunological findings in 17 patients. | 2008 | Bernengo MG; Quaglino P; Comessatti A; Ortoncelli M; Novelli M; Lisa F; Fierro MT | |
| Adult-onset cutaneous mastocytosis in monozygotic twins. | 2011 | Quaglino P; Mola F; Peroni A; Ortoncelli M; Di Bello C; Savoia P; Bernengo MG | |
| Evolution of different clinical patterns of cutaneous lesions in a suspected COVID-19 patient | 2020 | Quaglino P.; Fava P.; Cariti C.; Ortoncelli M.; Aimetti M.; Milan A.; Dapavo P.; Tonella L.; Ribero S.; Fierro M.T. | |
| Toxic epidermal necrolysis and role of immune dysregulation in a patient affected by coronavirus disease | 2021 | Parietti, Michele; Siliquini, Niccolò; Ortoncelli, Michela; Dapavo, Paolo; Stella, Maurizio; Verrua, Roberta; Ribero, Simone; Quaglino, Pietro | |
| Dupilumab induces a rapid decrease of pruritus in adolescents: A pilot real-life study | 2021 | Mastorino L.; Viola R.; Panzone M.; Avallone G.; Gallo G.; Ortoncelli M.; Cavaliere G.; Quaglino P.; Ribero S. | |
| Dupilumab-induced Urticaria | 2021 | Mastorino L.; Ortoncelli M.; Virginia B.; Rolla G.; Avallone G.; Cavaliere G.; Riccardo V.; Quaglino P.; Ribero S. | |
| Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study | 2021 | Dapavo P.; Siliquini N.; Mastorino L.; Avallone G.; Merli M.; Agostini A.; Cariti C.; Viola R.; Stroppiana E.; Verrone A.; Ortoncelli M.; Quaglino P.; Ribero S. | |
| Are serious ophthalmic adverse events on dupilumab treatment for atopic dermatitis dose related? | 2021 | Mastorino L.; Ortoncelli M.; Avallone G.; Quaglino P.; Ribero S. | |
| Atopic dermatitis, dupilumab and cancers: a case series | 2021 | Siliquini N.; Giura M.T.; Viola R.; Ribero S.; Panzone M.; Dapavo P.; Fierro M.T.; Ortoncelli M.; Quaglino P. | |
| Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study | 2021 | Patruno C.; Napolitano M.; Argenziano G.; Peris K.; Ortoncelli M.; Girolomoni G.; Offidani A.; Ferrucci S.M.; Amoruso G.F.; Rossi M.; Stingeni L.; Malara G.; Grieco T.; Foti C.; Gattoni M.; Loi C.; Iannone M.; Talamonti M.; Stinco G.; Rongioletti F.; Pigatto P.D.; Cristaudo A.; Nettis E.; Corazza M.; Guarneri F.; Amerio P.; Esposito M.; Belloni Fortina A.; Potenza C.; Fabbrocini G.; Angileri L.; Bianchelli T.; Borghi A.; Buligan C.; Calabrese G.; Calzavara Pinton P.; Caroppo F.; Chello C.; Dal Bello G.; Damiani G.; Fargnoli M.C.; Ferrillo M.; Galluzzo M.; Gori N.; Gualdi G.; Hansel K.; Macchia L.; Mariano M.; Nistico S.P.; Pertusi G.; Piras V.; Provenzano E.; Ravaioli G.M.; Ribero S.; Romanelli M.; Romita P.; Tolino E.; Trifiro C. | |
| Dupilumab in HIV-positive patients with atopic dermatitis: A long-term follow-up patient and a literature review | 2021 | Avallone G.; Trunfio M.; Giura M.T.; Siliquini N.; Viola R.; Orofino G.; Mastorino L.; Ortoncelli M.; Quaglino P.; Ribero S. | |
| Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study | 2021 | Patruno C.; Fabbrocini G.; Longo G.; Argenziano G.; Ferrucci S.M.; Stingeni L.; Peris K.; Ortoncelli M.; Offidani A.; Amoruso G.F.; Talamonti M.; Girolomoni G.; Grieco T.; Iannone M.; Nettis E.; Foti C.; Rongioletti F.; Corazza M.; Veneri M.D.; Napolitano M.; Angileri L.; Bianchelli T.; Borghi A.; Calabrese G.; Chello C.; Dal Bello G.; Dastoli S.; Ferrillo M.; Galluzzo M.; Gori N.; Hansel K.; Macchia L.; Piras V.; Provenzano E.; Ribero S.; Romanelli M.; Romita P. | |
| Efficacy of switching from adalimumab originator to adalimumab biosimilar in moderate to severe psoriasis patients: A Real-life experience in a tertiary referral centre | 2021 | Gallo G.; Rostagno E.; Siliquini N.; Stroppiana E.; Verrone A.; Ortoncelli M.; Quaglino P.; Dapavo P.; Ribero S. | |
| Head and neck severity index is associated to a significant worsening of quality of life in atopic dermatitis patients | 2021 | Ribero S.; Puglisi B.; Giura M.T.; Viola R.; Siliquini N.; Quaglino P.; Ortoncelli M. | |
| Effectiveness and Safety of Dupilumab for the Treatment of Atopic Dermatitis in Adult Cohort: a Real-Life Italian Tertiary Centre Experience. | 2022 | Ribero S, Giura MT, Viola R, Ramondetta A, Siliquini N, Cardone P, Tonella L, Quaglino P, Dapavo P, Panzone M, Ortoncelli M, Fierro MT. | |
| Lichen ruber planus arising during dupilumab treatment for atopic dermatitis | 2022 | Mastorino, Luca; Ortoncelli, Michela; Giura, Maria T; Avallone, Gianluca; Viola, Riccardo; Quaglino, Pietro; Ribero, Simone | |
| Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents | 2022 | Roccuzzo, Gabriele; Mastorino, Luca; Susca, Sara; Cariti, Caterina; Passerini, Stefania G; Sciamarrelli, Nadia; Borriello, Silvia; Macagno, Nicole; Sliquini, Niccolò; Avallone, Gianluca; Verrone, Anna; Stroppiana, Elena; Quaglino, Pietro; Ortoncelli, Michela; Dapavo, Paolo; Ribero, Simone | |
| Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis | 2022 | Mastorino L.; Siliquini N.; Avallone G.; Ortoncelli M.; Quaglino P.; Dapavo P.; Ribero S. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile